Receptor tyrosine kinases (RTKs) such as the fibroblast growth factor receptor (FGFR) and the epidermal growth factor receptor are overexpressed in a variety of cancers. In addition to overexpression, the FGFRs are found mutated in some cancers. The Src homology 2 domaincontaining phosphotyrosine phosphatase (SHP2) is a critical mediator of RTK signaling, but its role in oncogenic RTK-induced cell transformation and cancer development is largely unknown. In the current report, we demonstrate that constitutively activated FGFR3 (K/E-FR3) transforms NIH-3T3 cells, and that SHP2 is a critical mediator of this transformation. Infection of K/E-FR3-transformed 3T3 cells with a retrovirus carrying a dominant-negative mutant of SHP2 (C/S-SHP2) retarded cell growth, reversed the transformation phenotype and inhibited focus-forming ability. Furthermore, treatment of K/E-FR3-transformed NIH-3T3 cells with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Biochemical analysis showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that the C/S SHP2 mutant suppressed this effect via competitive displacement of interaction of the endogenous SHP2 with FRS2. However, the C/S SHP2 protein did not show any effect on receptor autophosphorylation, FRS2 tyrosine phosphorylation or interaction of Grb2 with K/E-FR3 or FRS2. Together, the results show that K/E-FR3 is transforming and that the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, are important for K/E-FR3-induced transformation.
Introduction
The family of fibroblast growth factor receptors (FGFRs) consist of at least four tyrosine kinases that share significant structural homology (Jaye et al., 1992; Partanen et al., 1992; Johnson and Williams, 1993) .
Characteristic structural features include the presence of three immunoglobulin-like domains in the extracellular region, a single transmembrane domain, and a cytosolic region with a split tyrosine kinase domain and tyrosine autophosphorylation sites (Johnson and Williams, 1993) . The extracellular domain possesses highly conserved Cys residues, which maintain structural integrity via formation of intramolecular disulfide bonds (Johnson and Williams, 1993; Dickson et al., 2000) . Maintenance of this structural integrity is important not only for specific interaction with FGF molecules, but also for physiological regulation of FGFRs . In the absence of an appropriate ligand, FGFRs are inactive, but upon binding to FGFs, they form dimers, which lead to tyrosine autophosphorylation, recruitment of SH2 and PTB domain-containing signaling proteins such as FGFR substrate 2 (FRS2), phosphatidylinositol 3-kinase (PI3K), growth factor receptor binder 2 (Grb2), Src homology domain-containing phosphotyrosine phosphatase 2 (SH-PTP2, also called SHP2) and phospholipase C gamma (PLCg) (Plotnikov et al., 1999; Dickson et al., 2000) . The net effect is transmission of FGFR signals that cause cellular responses including cell growth or differentiation depending on cell context and developmental stage of the organism.
Several missense point mutations of FGFRs, particularly FGFR1, FGFR2 and FGFR3, that activate the TK domain have been reported (Rousseau et al., 1996; Webster and Donoghue, 1997b) . Most of these mutations occur in the extracellular and transmembrane regions, and several of these result in the creation or elimination of Cys residues (Webster and Donoghue, 1997b) . Either of these processes give rise to free Cys residues that mediate intermolecular disulfide linkage and dimer formation mimicking ligand binding and receptor activation (Neilson and Friesel, 1996; Rousseau et al., 1996; Webster and Donoghue, 1997b; Robertson et al., 1998) . Point mutations that do not involve Cys residues have also been reported (Li et al., 1997; Monsonego-Ornan et al., 2000; Winterpacht et al., 2000) . These substitutions have also been shown to be activating. Point mutations of the cytosolic region were primarily reported in FGFR3, and they are relatively fewer. These include Asn540Lys, Lys650Glu/Met or stop codon 807Gly/Arg/Cys (Li et al., 1999; Tavormina et al., 1999; Bellus et al., 2000) . The Lys650Glu/Met occurs in the activation loop of the TK domain and is highly activating probably via elimination of the inhibitory effect of the activation loop on substrate binding. The mutation that eliminates the stop codon results in the production of a longer protein, but how this results in receptor activation is unknown (Webster and Donoghue, 1997b) .
Activating mutations of FGFRs have been shown to be the causes of various developmental abnormalities, particularly of the skeletal and the nervous systems in humans. For instance, various point mutations of FGFR1 and 2 have been shown to be the causes of the Pfeiffer, Apert and Crouzon syndromes (Wilkie et al., 1995a, b; Wilkie and Wall, 1996; Iseki et al., 1997; Wilkie and Goodacre, 1997; Anderson et al., 1998; Wilkie and Morriss-Kay, 2001 ). On the other hand, point mutations in FGFR3 cause severe skeletal disorders that result in various forms of dwarfism or Thanatophoric Dysplasia (TD) I and TDII that result in neonatal lethality (Rousseau et al., 1996; Webster and Donoghue, 1997b; Tavormina et al., 1999; Bellus et al., 2000) . TDI is caused by point mutations that create free Cys residues (e.g. Arg248Cys, Ser249Cys, Gly370Cys, Tyr373Cys) or Stop codon mutations that result in a longer protein (e.g. Stop807Gly, Stop807Arg, Stop807Cys), whereas TDII is by Lys650E substitution (Rousseau et al., 1996; Webster and Donoghue, 1997b; Tavormina et al., 1999; Bellus et al., 2000) .
In addition to their involvement in developmental abnormalities of the skeletal and nervous system, constitutively activated mutants of FGFRs have also been found in certain types of tumors. For instance, activating point mutations of FGFR2 and FGFR3 were identified in gastric and colorectal cancers, respectively (Jang et al., 2001) . In addition, activating mutations of FGFR3 were found in bladder and cervical carcinomas as well as in multiple myeloma (MM) (Hallek et al., 1998; Chesi et al., 2002; Van Rhijn et al., 2002) . Interestingly, the most frequent finding in MM is the deregulated expression of functional FGFR3 due to translocation to the immunoglobulin heavy chain switch region (the t(4:14)(p16:q32) translocation), a hot spot of chromosomal abnormality in lymphoid cells (Chesi et al., 1997; Richelda et al., 1997) . Further investigations revealed that activating mutations on FGFR3 may follow translocation, which may be correlated with progression to malignancy. These findings are consistent with the involvement of FGFRs in cancer, and as a result, particular attention has been given to FGFR3.
Efforts geared at elucidating the transforming potential of activated FGFR3 have come up with inconclusive results. One group reported that only the myristylated version of the cytosolic domain of K650E-FGFR3 (K/ E-FR3) can transform 3T3 fibroblasts (Webster and Donoghue, 1997a; Robertson et al., 1998) . Another group reported that the full-length K/E-FR3 (or Y373C-FR3) could transform 3T3 cells if a different expression system is used (Chesi et al., 2001) . Furthermore, investigations on the interleukin-6-dependent murine B9 cell line show that expression of K/E-FR3 induces IL-6 independence, decreased apoptosis and enhanced proliferation (Plowright et al., 2000) . Although these results suggest that activated FGFR3 could be oncogenic, the subject is clearly unsettled, and thus requires further investigation.
Investigations aimed at defining signaling pathways induced by K/E-FR3 or other activated forms have shown activation of various signaling pathways. In one case, it was shown that constitutively active FR3 activates the signal transducers and activators of transcription (STATs), but not the extracellular signalregulated kinase 1 and 2 (ERK1/2) (Legeai-Mallet et al., 1998; Li et al., 1999) . And in another case, it was shown that constitutively active FR3 s activate the STATs, the ERK1/2 and PI3K (Hart et al., 2000 (Hart et al., , 2001 . Again, the issue seems unsettled. In addition, data on the functional relevance of activation of these pathways are lacking. Thus, further experimentation on these questions is warranted.
Another interesting signaling molecule shown to be essential for RTK-induced signaling is SHP2. It was shown to be a critical mediator of FGFR signals in development (Saxton et al., 1997 (Saxton et al., , 2000 . SHP2 possesses two tandemly arranged SH2 domains in its N-terminal region and a phosphatase domain in its C-terminal domain (Feng et al., 1993 Hallek et al., 1998; Chesi et al., 2002; Van Rhijn et al., 2002) . It also possesses a stretch of proline-rich sequences and tyrosine phosphorylation sites in its extreme C-terminal region. Both SH2 domains and the phosphatase domain have been shown to be absolutely essential for the biological activity of SHP2 (Deb et al., 1998) . Deletion of the N-SH2 or the phosphatase domain or mutation of the conserved cysteine residue to serine (C459S) in the active site of the phosphatase domain abrogates the biological activity of SHP2 (Feng et al., 1993 . However, no biological role has been definitively ascribed to the tyrosine phosphorylation sites or the proline-rich region. Although the tyrosine phosphorylation of SHP2 was noted, what this means in terms of K/E-FR3-induced transformation was not investigated. Given previous reports that show that tyrosine phosphorylation of SHP2 could be dispensable in FGFR signaling, the subject requires further investigation.
In the current report, we provide evidence that highlight the oncogenicity of K/E-FR3, and clarify the significance of the activation of certain signaling pathways. We specifically show that the Ras-ERK and the PI3K-Akt signaling pathways are essential for K/E-FR3-induced transformation of NIH-3T3 cells, and that SHP2, by acting upstream of Ras, plays a pivotal role in transducing these signals. Based on these findings, we propose that SHP2 and/or its substrates could be potential targets for therapeutic intervention studies for the treatment of cancer.
Results
Recent reports show that FGFR3 might be an important player in the development and progression of different types of cancers. Here, we present the results of our investigation on the transforming potential of K/E-FR3, the signaling pathways it activates and the significance of these activations for transformation.
K/E-FR3 transforms NIH-3T3 cells 3T3 cells were transfected with WT-FR3 or K/E-FR3, and a focus assay performed (see Materials and methods). Cells transfected with the K/E-FR3 formed several foci, whereas those transfected with the WT-FR3 did not (Figure 1) . Similarly, cells transfected with the oncogenic Vav (positive control) formed several foci. Similar results were obtained using soft agar colony assay (data not shown). These results indicated that K/ E-FR3 transforms 3T3 fibroblasts.
Characterization of K/E-FR3-tranformed 3T3 cells
For further experimentation, clones of 3T3 cells expressing K/E-FR3 were isolated as described in Materials and methods, and expression of K/E-FR3 analysed by immunoblot. All the clones picked showed expression of K/E-FR3 to varying degrees (data not shown). A clone that showed a relatively high amount of K/E-FR3 expression was selected for further experimentation, and termed K/E-FR3C. Anti-pY immunoblot analysis of total cell lysates from this cell line showed that K/E-FR3 induced tyrosine phosphorylation of cellular proteins in the absence of ligand (Figure 2a, left) , and this did not occur in the parent 3T3 cells (Figure 2a , right). Reblot with anti-FR3 antibody showed that it is expressed in the transformants, but not in the parent 3T3 cells, making it an ideal cell for studying constitutive signaling by an oncogenic version of FR3. Furthermore, microscopic examination revealed that the K/E-FR3C has acquired an elongated, refractile and spindle-shaped morphology reminiscent of transformed cells ( Figure 2b ).
Previous work on activation of the various signaling pathways by the K/E-FR3 seems to be disparate. We thus analysed total cell lysates for ERK and Akt activation (as a readout for activation of the Ras-ERK and PI3K pathways, respectively) using phosphospecific antibodies. As shown in Figure 2c , ERK1/2 (top panel) and Akt (middle panel) were highly phosphorylated in the K/E-FR3C, but not in the parent 3T3 cells. Reblotting the same membrane with anti-panAkt antibody showed that there was comparable amount of 
SHP2 is required for K/E-FR3-induced transformation
SHP2 was shown to be a critical mediator of RTK signaling, particularly signaling by FGFRs, but its role in K/E-FR3-induced transformation has not been investigated. To address this question, we infected the K/E-FR3C with recombinant retroviruses expressing the WT or the dominant-negative SHP2 (C/S SHP2) and analysed three parameters of transformation: morphological changes, cell growth and focus-formation ability. A retrovirus-carrying vector only was used as a control (see Materials and methods for details). Infection with the vector or the WT SHP2 virus did not cause any morphological changes, whereas infection with the C/S SHP2 virus reversed the transformed phenotype ( Figure 3a ). The morphology of the C/S-infected cells became similar to that of the parent 3T3 cells (compare 3T3 vs K/E-FR3C-C/S). These results indicated that SHP2 was required for transformation induced by K/E-FR3.
In addition to changes in morphology, we observed that the K/E-FR3C infected with C/S required more time to reach confluency than those infected with the vector or the WT SHP2 virus, suggesting that SHP2 might also be affecting cell growth. We thus determined the rate of cell proliferation. K/E-FR3C infected with C/ S was retarded in its growth rate, reaching only threefold of initial value in 48 h when the vector-or the WT-infected cells had reached sixfold. At 72 h time point, the C/S-infected cells were only sevenfold of initial value when the vector-or the WT-infected cells had reached 15-fold (Figure 3b ). Thus, SHP2 was required for enhanced cell growth induced by K/E-FR3.
The role of SHP2 in K/E-FR3-induced transformation was further investigated by evaluating its effect on the focus-forming ability of the K/E-FR3C. K/E-FR3C infected with the vector or WT virus formed many foci, whereas those infected with the C/S virus formed fewer and smaller foci (Figure 3c ). Together, these results showed that SHP2 plays a pivotal role in K/E-FR3-induced transformation by regulating cell morphology, growth rate and focus-forming ability.
SHP2 was required for K/E-FR3-induced activation of ERK1/2 and Akt
We showed that K/E-FR3 activates the ERK and the Akt signaling pathways (Figure 2c ). We also demonstrated that the C/S protein retarded the growth of K/E-FR3C, reversed its transformed phenotype and inhibited its focus-forming ability (Figure 3) . Furthermore, previous work has shown that SHP2 is an essential mediator of RTK-induced ERK activation. We thus investigated the effect of the C/S protein on K/E-FR3-induced ERK1/2 and Akt activation. Total cell lysates prepared from parent 3T3 cells or the K/E-FR3C infected with the vector, WT or C/S virus were analysed 
PD98059 and LY294002 compounds inhibit focus formation by K/E-FR3C
We demonstrated that K/E-FR3 activates ERK1/2 and the Akt (Figures 1c and 4) . However, it was not clear whether these pathways were important for K/E-FR3-induced transformation. We addressed this point by employing PD98059, a specific MEK inhibitor, and LY294002, a specific PI3K inhibitor. Before actual treatment studies, we carried out titration studies to determine the concentration of each drug that would be sufficient to cause specific inhibition without causing other adverse effects. We treated the K/E-FR3C with either drug for 48 h at concentrations ranging from 10 to 100 mm and lysates prepared from these cells were analysed by immunoblotting with anti-phospho-ERK1/2 and anti-phospho-Akt antibodies. We found that the PD and LY coumpounds specifically inhibited ERK1/2 and Akt phosphorylation, respectively, without any side effect even at the highest concentration used (data not shown). We chose 40 mm PD and 10 mm LY as minimum concentrations with sufficient inhibitory effect for our further studies. Addition of either drug inhibited the focus-forming ability of the K/E-FR3C with the LY compound showing a much higher effect at four times less concentration than the PD compound ( Figure 5 ). These results demonstrated that both the ERK and the PI3K signaling pathways were essential for K/E-FR3-induced transformation.
Ras activation by K/E-FR3 requires functional SHP2
We demonstrated that SHP2 was required for K/E-FR3-induced ERK1/2 and Akt activation ( Figure 5 ). Previous reports also show that SHP2 is essential for RTK-induced ERK activation. However, its mechanism of action is not known. Also, how SHP2 affects Akt activation is not known. To address these questions, we investigated the role of SHP2 on K/E-FR3-induced Ras activation (see Materials and methods for details). K/E-FR3-induced Ras activation was inhibited by infecting K/E-FR3C with the C/S virus, but not with the vector or the WT (Figure 6 , top). Anti-Ras immunoblot of the corresponding total cell lysates showed that there was comparable amount of Ras protein in all cases (Figure 6 , bottom). These results provided two important insights: that SHP2 was required for Ras activation by K/E-FR3 and that its site of action in the Ras-ERK pathway was at the level or upstream of Ras. Furthermore, these results suggested that the effect of SHP2 on Akt could be due to its effect on Ras, since activated Ras was shown to bind and activate the p110 subunit of PI3K.
SHP2 was not required for several signaling events upstream of Ras
Inhibition of K/E-FR3-induced Ras activation by the C/S SHP2 protein indicated that SHP2 might be acting upstream of Ras in RTK signaling. We thus investigated known upstream signaling events to see if they were Figure 4 Effect of dominant-negative SHP2 on ERK1/2 and Akt activation by K/E-FR3. Total cell lysates prepared from the indicated cells were analysed for activation of ERK1/2 (a, top) or Akt (b, top) using phosphospecific antibodies. The membranes were reblotted for the presence of comparable amount of protein in all lanes using panERK2 (a, bottom) or panAkt (b, bottom) antibody. The blots presented were representatives of at least three independent experiments Figure 5 Effect of PD98059 or LY294002 on focus-forming ability of K/E-FR3C. K/E-FR3C were assayed for focus formation in the presence of 40 mm PD98059 or 10 mm LY294002. Pictures were taken as in Figure 3c Role of SHP2 in transformation by K/E-FR3 YM Agazie et al affected by SHP2. Lysates prepared from K/E-FR3C infected with the vector, the WT or the C/S SHP2 viruses were subjected to immunoprecipitation with anti-FR3 and immunoblot with the indicated antibodies ( Figure 7 ). Immunoblot with anti-pY antibody showed that the autophosphorylation of K/E-FR3 was not affected by the C/S SHP2 protein (Figure 7a, top) . In addition, there was no difference in the tyrosine phosphorylation of the unknown FR3-associated proteins except for a protein of approximately 95 kDa that was present only in the C/S-infected cells. Reblotting the membrane with anti-FGFR3 antibody showed that comparable amount of protein was present in all lanes (Figure 7a, middle) . Further reblotting with anti-Grb2 showed that its association with K/E-FR3 was not affected by expression of either the WT or C/S SHP2 protein (Figure 7a, SUC1 from the same set of lysates used above, and then immunoblotted the membrane with anti-pY. As shown in Figure 7b (top), K/E-FR3 induced the tyrosine phosphorylation of FRS2 and the associated p60 and p40. Interestingly, neither the tyrosine phosphorylation of these proteins (Figure 7b, top) nor the association of Grb2 with FRS2 was affected by expression of the WT or the C/S SHP2 protein (Figure 7b, bottom) . Further reblotting with anti-FRS2 antibody showed that there was comparable amount of protein in all lanes (Figure 7b, middle) . In the same anti-FRS2 blot, it is possible to note the phosphorylation-dependent shift in molecular weight, which is characteristic of FRS2. Thus, SHP2 had no apparent effect in receptor autophosphorylation, phosphorylation of FRS2 or the association of Grb2. Together, these results suggested that SHP2 might be acting between the receptor or the adaptor protein FRS2 and Ras. In agreement with previous reports, we did not detect any direct or indirect interaction between FRS2 and K/E-FR3 or vice versa (data not shown), indicating that activation of Ras by K/E-FR3 could be achieved in two parallel ways -via FRS2 and via the 'receptor' itself.
FRS2-associated phosphatase assay
It was previously shown that SHP2 directly interacts with FRS2. Furthermore, elimination of SHP2-binding site on FRS2 blocks FGF signaling (Hadari et al., 1998) . As shown in Figures 3 and 4 , expression of the C/S protein inhibited K/E-FR3-induced transformation, and suppressed Ras, ERK1/2 and Akt activation. It was thus of interest to determine FRS2-associated PTP activity to see if it had been affected by expression of the C/S protein. To address this question, FRS2 was precipitated with p13
SUC1
, and the associated in vitro PTP activity was determined using P-nitrophenyl phosphate as a substrate. As compared to NIH-3T3 cells, FRS2-associated PTP activity was 13-, 18-and fourfold for K/ E-FR3C, K/E-FR3C-WT and K/E-FR3C-C/S, respectively (Figure 8a ). Immunoblot analysis of the same precipitates with anti-FRS2 antibody showed the presence of comparable amount of FRS2 in all lanes (Figure 8b, top) . Reblotting the same membrane with anti-SHP2 antibody revealed that FRS2-associated SHP2 was present in all K/E-FR3-expressing cells with slight increase in K/E-FR3C-WT and K/E-FR3C-C/S cells; a basal level FRS2-associated SHP2 was detected in the control NIH-3T3 cells (Figure 8b, bottom) . These results suggest that expression of the C/S protein results in loss of FRS2-associated SHP2 activity directly linking SHP2 to K/E-FR3-induced transformation.
Discussion
Overexpression with or without constitutive activation of RTKs has been implicated in tumor initiation and/or progression to malignancy. In fact, overexpression of RTKs in tumors is an indication of poor prognosis. Thus, complete understanding of signaling by RTK or their downstream effector proteins would be critical in our endeavor to mitigate cancer. The phosphotyrosine phosphatase SHP2 has been shown to be an essential downstream mediator of RTK signaling. However, its role in tumor initiation and cancer development is virtually unknown. In the current report, we have presented evidence that show that expression of K/E-FR3 transforms 3T3 fibroblasts and that the Ras-ERK and the PI3K-Akt signaling pathways are essential for this transformation. Furthermore, we have demonstrated that SHP2 is a positive mediator of K/E-FR3-induced transformation by regulating the activation of ERK1/2 and Akt at the level of Ras.
Previous reports on the transforming potential of K/ E-FR3 were inconclusive. In one case, it was reported that the full-length K/E-FR3 is nontransforming, but a myristylated version of the cytosolic domain (containing the tyrosine kinase domain and authophosphorylation sites) is transforming (Webster and Donoghue, 1997a; Robertson et al., 1998) . In another case, the full-length protein was found to be transforming in the same cell line (Chesi et al., 2001) . Using the expression system used in the latter case, we found that the full-length protein (K/E-FR3) is transforming to 3T3 fibroblasts. Thus, the reason behind these differences could be the level of expression achieved. Nonetheless, our results confirm that the K/E-FR3 protein has the potential to be oncogenic. Therefore, FR3 overexpression with or without activating mutations found in a variety of cancers (Ueki et al., 1995; Hallek et al., 1998; Chesi et al., 2002; Van Rhijn et al., 2002) may imply its involvement in tumor initiation and/or progression.
We demonstrated that the C/S SHP2 protein retarded the growth of K/E-FR3C, reversed its transformed phenotype and inhibited its focus-forming ability (Figure 3) , suggesting that SHP2 is essential for K/E-FR3-induced transformation. Thus, our results provide new insights on the role of SHP2 in FR3-induced transformation, which were not shown before. SHP2 possesses two tandemly arranged SH2 domains in its Nterminal region and a phosphatase domain in its Cterminal domain (Feng et al., 1993; . These domains are absolutely essential for the biological activity of SHP2 (Deb et al., 1998) , but the Cterminal region tyrosine phosphorylation sites seem to be dispensable in FGFR signaling (Van Vactor et al., 1998; O'Reilly et al., 2000) . The C/S SHP2 protein used in our experiments was unable to transduce K/E-FR3 signals, suggesting that the PTPase activity of SHP2 is important. Although we did not investigate the importance of the SH2 domains, it is obvious that SHP2 requires these domains to translocate to the plasma membrane since it acts upstream of Ras. The importance of SH2 domains in SHP2 biological activity has previously been shown (Deb et al., 1998; Van Vactor et al., 1998; O'Reilly et al., 2000) .
K/E-FR3 activates the Ras-ERK and the PI3K-Akt signaling pathways, and SHP2 is a critical mediator of activation of these pathways. Inhibition of ERK activation with PD98059 or PI3K activation with LY294002 inhibited foci formation by the K/E-FR3C, suggesting that the functioning in concert of both pathways is essential for transformation (Figures 4-6 ). On top of this, we observed that the effect of the LY compound was more drastic than the PD compound, which may indicate the relative contribution of each pathway. In our previous report (Agazie et al., 2002) , we demonstrated that transformation by the V-SEA tyrosine kinase oncogene requires the in-tandem functioning of both these pathways. Thus, our findings with K/ E-FR3 provide evidence that oncogenic RTKs may utilize a common mechanism in transforming cells.
Activation of Ras by RTKs involves the recruitment of the Ras nucleotide exchange factor son of sevenless (SOS) to the plasma membrane where Ras is located. Grb2, which is constitutively associated with SOS, mediates the recruitment process by interacting with tyrosine-phosphorylation sites either on the RTKs or adaptor proteins via its SH2 domain. We demonstrated K/E-FR3 becomes autophosphorylated, and also induces tyrosine phosphorylation of FRS2, an adaptor protein known to transduce FGFR signals (Melillo et al., 2001; Lax et al., 2002) . We also showed that Grb2 interacts with the receptor itself and the adaptor protein FRS2, and this interaction was not affected by expression of the C/S SHP2, protein, suggesting that translocation of SOS to the plasma membrane was not affected. However, in contrast to previous reports on FGFR1 (Xu et al., 1998; Ong et al., 2000; Melillo et al., 2001) , we were unable to show the interaction of FRS2 with K/E-FR3, which may suggest that FRS2 does not directly or indirectly associate with FR3. Thus, colocalization to the plasma membrane may be sufficient for the induction of FRS2 tyrosine phosphorylation by K/ E-FR3. From these results, it is possible to infer several important insights: (1) that K/E-FR3 induces the tyrosine phosphorylation of the adaptor protein FRS2, (2) that K/E-FR3 activates Ras in at least two parallel ways -via FRS2 and via the 'receptor' itself, and (3) that SHP2 might be acting between the receptor or the adaptor protein FRS2 and Ras. Consistent with our results, it was demonstrated that the activation of ERK1/2 by constitutively active SHP2 mutants could be inhibited by the dominant-negative Ras (O'Reilly et al., 2000) . However, how SHP2 transduces signals from RTKs to Ras activation remains to be investigated. It was previously shown that GTP-Ras could interact with p110 subunit of PI3K and activate the enzyme. Therefore, inhibition of PI3K activation by the C/S SHP2 could be due to its effect on Ras activation.
In order to establish a direct link between K/E-FR3-induced transformation and SHP2, we conducted SHP2 PTPase assay, and found that expression of the C/S protein resulted in loss of FRS2-associated PTP activity. The likely explanation could be competitive replacement of the endogenous SHP2 by the C/S protein on FRS2. Our results are thus consistent with previous reports, which showed that interaction of SHP2 with FRS2 is essential for mediating FGF-induced mitogenic and developmental signals (Hadari et al., 1998; Ong et al., 2000; Lax et al., 2002) . Furthermore, SHP2 was found to be essential in v-Src-induced transformation (Hakak et al., 2000) . Therefore, SHP2 could be a critical mediator of oncogenic tyrosine kinases including K/E-FR3.
Similar to the observations made by others in SHP2 studies (Shi et al., 2000) , we observed the tyrosine phosphorylation of the 95 kDa protein in K/E-FR3C expressing the C/S SHP2 protein. Although the identity of this protein is currently unknown, it would be interesting to isolate and identify this protein, which may provide key insights into SHP2 mechanism of action. The recent development of an efficient trapping mutant of SHP2 (Agazie & Hayman, 2003) could be a valuable reagent for this investigation.
In summary, we demonstrated that K/E-FR3 transforms NIH-3T3 cells and that expression of dominantnegative mutant of SHP2 in the transformed cells retards their growth, reverses the transformation phenotype and inhibits their focus-forming ability. We also showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that expression of the C/ S-SHP2 suppressed this effect. Furthermore, treatment of K/E-FR3C with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Therefore, K/E-FR3 is transforming, and the functioning of the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, is important for K/E-FR3-induced transformation. Overexpression with or without activating mutations of FR3 or the other family members found in a variety of cancers may imply their involvement in tumor initiation and/or progression. Therefore, SHP2 or its biological substrates could be potential targets for therapeutic intervention studies against cancer.
Materials and methods

Cells, cell culture, antibodies and other reagents
The parent cell types used in this study were COS-1 and NIH-3T3. Generation of 3T3 cells that stably express K/E-FR3 or K/E-FR3 plus SHP2 was as outlined below. All cell lines were grown in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal calf serum, and maintained at 371C with 7% CO 2 . The fibroblast growth factor (FGF) was purchased from GIBCO-BRL. Anti-phospho-ERK1/2 and anti-pan-ERK2 antibodies were from New England Biolabs, anti-PTP1D and anti-Ras monoclonal antibodies were from Transduction Laboratories, and anti-phosphotyrosine monoclonal antibody (4G10) was a gift from Dr Morrison. The polyclonal antibodies against SHP2 (Park and Hayman, 1999) and FGFR3 (this report) were raised by injection of rabbits with GST fusion of the N-and C-terminal regions, respectively, and the monoclonal antibody against FGFR3 was raised against the extracellular domain (Lin et al., 1996) . Horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham. For fluorescent quantitation of band intensities, alkaline phosphatase-conjugated anti-rabbit and anti-mouse secondary antibodies were purchased from ZYMED, whereas the AttoPhos fluorescent substrate system was from Promega.
Plasmid construction, cell transfection and preparation of lysates
Expression plasmids for full-length WT-FGFR3 or K650E-FGFR3, hereafter referred to as WT-FR3 and K/E-FR3, respectively, were constructed as follows. Both inserts were cut out from pcDNA3 with BamHI and EcoRV and then inserted into pCEFL vector using the same restriction sites. This vector contains EF-1a promoter that was previously shown to confer higher expression (Li et al., 1997) . Construction of expression plasmids for WT-SHP2 or C459S-SHP2 was described previously (Park and Hayman, 1999) .
Production of recombinant retrovirus expressing WT-or C459S-SHP2
A retroviral vector termed REBNA/IRES/GFP was kindly provided by Dr Oleksi Petrenko (SUNY at Stony Brook, Stony Brook, NY, USA). This viral vector contains a puromycin resistance gene for selection in packaging cells, and a blastocidin gene for selection in the cell line infected with the recombinant retrovirus. WT-SHP2 and C495S-SHP2, hereinafter referred to as WT and C/S, respectively, were cut out with EcoRI from the pMT2 vector and then cloned into the retroviral vector digested with the same enzyme. Direction of cloning was diagnosed by digestion with BglII restriction enzyme that has a unique site both in the vector and the insert. To produce the virus, the vector carrying the various SHP2 proteins was transfected into packaging phoenix E cells using the FuGENE transfection reagent. After 72 h of incubation, 2 mg/ml puromycin was added to cells to remove untransfected phoenix cells and at the same time to increase the liter of the virus expressing the SHP2 proteins. After 48 h under puromycin, resistant cells were split and incubated in a fresh medium until they were confluent, at which time the supernatant containing the virus was harvested.
Generation of cell lines expressing K/E-FR3 or K/E-FR3 plus SHP2 3T3 cells expressing K/E-FGR3 were generated by transfecting with K/E-FR3 in pCEFL plasmid using the FuGene transfection reagent as recommended by the manufacturer (GIBCO-BRL). The WT-FR3 in the same vector was used as a control. After 14 days of incubation, plates were examined for formation of foci under a microscope. To isolate clones of K/E-FR3-expressing cells, several foci were picked, grown separately and then seeded into soft agar as described previously (Agazie et al., 2002) . After incubation for 6 days, separate colonies were picked and expanded. The expression of FR3 was determined by immunoblot analysis. Clones stably expressing relatively higher levels of K/E-FR3 were saved and the one used in this report is termed K/E-FR3C.
Cells stably coexpressing K/E-FR3 and the WT or the C/S SHP2 protein were produced by infecting K/E-FR3C cells with the recombinant retroviruses described above. Infection of cells was performed in the presence of 5 mg/ml polybrene (Sigma). After 24 h of incubation, blastocidin was added to the medium at a final concentration of 5 mg/ml to remove uninfected cells. A population of cells resistant to blastocidin was taken as a cell line expressing the desired protein or proteins. These cells were termed K/E-FR3C-Vec, K/E-FR3C-WT and K/E-FR3C-C/S.
Focus-formation assay
To study the ability of K/E-FR3C or its derivatives to form foci, 10 4 cells of each line were first mixed with 10 5 of the parent 3T3 cells and then seeded onto 6 cm dishes in duplicate. Cells were maintained in DMEM containing 5% fetal calf serum with replenishment every 3 days. After 10 days of incubations, colonies were stained with Giemsa and photographed. To study the effect of inhibition of the ERK or the PI3K pathways on focus-forming ability of the K/E-FR3C, 40 mm PD98059 or 10 mm LY294002 was added to the growth medium and cells assayed as above.
Immunoprecipitation and immunoblotting
All immunoprecipitation experiments were performed by overnight incubation at 41C with an additional incubation for 2 h after addition of sepharose beads. Unless otherwise specified, immunocomplexes captured on sepharose beads were washed three times with cell lysis buffer and bound proteins eluted by boiling with Laemmli sample buffer and then run on 10% denaturing polyacrylamide gel. After transfer onto nitrocellulose membrane, blocking was done by incubation with 3% bovine serum albumin. Primary antibody staining was done overnight at 41C or for 2 h at room temperature and secondary antibody staining was for 1 h at room temperature. In all cases, the chemiluminescence method was used for detecting bands. The same gel separation and detection procedures were used for the analysis of total cell lysates.
Analysis of Ras activation
Ras activation was determined by making use of the interaction of GTP-Ras with Raf-1 (Taylor and Shalloway, 1996) . A GST-fusion protein of the Ras-binding domain of Raf-1 (Raf-RBD) was kindly provided by Dr Shalloway (Cornell University, Ithaca, NY, USA). Lysates of bacteria expressing the fusion protein were prepared as described previously (Taylor and Shalloway, 1996) with an additional step of lysate clearing by passing through a syringe filter (0.2 mm pore size). GST-RBD was purified on glutathione sepharose beads (20 ml packed volume, B1 mg GST-RBD per sample) by incubation for 30 min at 41C, and washing three times with bacterial lysis buffer and two times with eukaryotic cell lysis buffer (see above). Lysates of COS-1 cells (see individual experiments for details) were added to beads, incubated further for 1 h, washed five times with cell lysis buffer, bound proteins eluted by boiling for 10 min with Laemmli sample buffer and resolved on 12% SDS-PAGE. Separated proteins were transferred onto a nitrocellulose membrane, blocked with 3% BSA and probed with anti-Ras monoclonal antibody.
FRS2-associated PTPase assay
To determine FRS2-associated PTP activity, we conducted in vitro PTPase assay using the artificial substrate, P-nitrophenyl phosphate. Briefly, FRS2 was precipitated from the corresponding lysates (Figure 8 ) using p13 SUC1 covalently bound to sepharose beads (Upstate Biotechnology). The precipitates were washed three times with cell lysis buffer (see above) and once with PTPase buffer. The reactions were carried out in 200 ml volume as described previously (Denu et al., 1995) in the presence of 1 mm substrate.
